Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Cancer Research
|
January 15, 1989
Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer
C F Rochlitz, G K Scott, J M Dodson, et al.
The Journal of Biological Chemistry
|
May 20, 2000
Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides
S Y Chiang, R W Burli, C C Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 1994
Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay
P Eng Tan, C C Benz, C Dollbaum, et al.
Cancer Research
|
September 1, 1997
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
S R Johnston, B Lu, M Dowsett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer
A D Thor, S Liu, S Edgerton, et al.
Investigational New Drugs
|
January 1, 1995
Developing gossypol derivatives with enhanced antitumor activity
X S Liang, A J Rogers, C L Webber, et al.
Cancer
|
June 15, 1993
Tumor labeling indices of primary breast cancers and their regional lymph node metastases
W H Goodson, B M Ljung, D H Moore, et al.
Breast Cancer Research and Treatment
|
January 1, 1993
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C C Benz, G K Scott, J C Sarup, et al.
Oncogene
|
February 15, 2001
Ets regulation of the erbB2 promoter
G K Scott, C H Chang, K M Erny, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
August 8, 2001
Tumor targeting using anti-her2 immunoliposomes
J W Park, D B Kirpotin, K Hong, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Cancer Research
|
January 15, 1989
Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer
C F Rochlitz, G K Scott, J M Dodson, et al.
The Journal of Biological Chemistry
|
May 20, 2000
Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides
S Y Chiang, R W Burli, C C Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 1994
Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay
P Eng Tan, C C Benz, C Dollbaum, et al.
Cancer Research
|
September 1, 1997
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
S R Johnston, B Lu, M Dowsett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer
A D Thor, S Liu, S Edgerton, et al.
Investigational New Drugs
|
January 1, 1995
Developing gossypol derivatives with enhanced antitumor activity
X S Liang, A J Rogers, C L Webber, et al.
Cancer
|
June 15, 1993
Tumor labeling indices of primary breast cancers and their regional lymph node metastases
W H Goodson, B M Ljung, D H Moore, et al.
Breast Cancer Research and Treatment
|
January 1, 1993
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C C Benz, G K Scott, J C Sarup, et al.
Oncogene
|
February 15, 2001
Ets regulation of the erbB2 promoter
G K Scott, C H Chang, K M Erny, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
August 8, 2001
Tumor targeting using anti-her2 immunoliposomes
J W Park, D B Kirpotin, K Hong, et al.
Page
of 8